THE ROLE of the 5-HT Ta RECEPTOR in CENTRAL CARDIOVASCULAR REGULATION Printed By: Duphar B.V

Total Page:16

File Type:pdf, Size:1020Kb

THE ROLE of the 5-HT Ta RECEPTOR in CENTRAL CARDIOVASCULAR REGULATION Printed By: Duphar B.V THE ROLE OF THE 5-HT tA RECEPTOR IN CENTRAL CARDIOVASCULAR REGULATION Printed by: Duphar B.V. C.J. van Houtenlaan 36 1381 CP Weesp The Netherlands Isbn 90-9004025-0 Cover design by F. W. Pompe. © G.H. Dreteler, Elst, 1991 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying. recording, or otherwise. without written permission from the publisher. THE ROLE OF THE S-HT1A RECEPTOR IN CENTRAL CARDIOVASCULAR REGULATION DE ROL VAN DE 5-HT1A RECEPTOR IN DE CENTRALE CARDIOVASCULAIRE REGULA TIE PROEFSCHRIFT TER VERKRIJGING VAN DE GRAAD VAN DOCTOR AAN DE ERASMUS UNIVERSITEIT ROTTERDAM OP GEZAG VAN DE RECTOR MAGNIFICUS PROF.DR. C.J. RIJNVOS EN VOLGENS BESLUIT VAN HET COLLEGE VAN DEKANEN DE OPENBARE VERDEDIGING ZAL PLAATSVINDEN OP WOENSDAG 27 MAART 1991 OM 15.45 UUR door GERRIE HENDRIKA DRETELER GEBOREN TE DELDEN PROMOTIECOMMISSIE PROMOTOR: PROF.DR. P.R. SAXENA OVERIGE LEDEN: PROF.DR. A.J. MAN IN 'T VELD PROF.DR. P.A. VAN ZWIETEN DR. J.F.M. SMITS CO-PROMOTOR: DR. W. WOUTERS The investigations described in this thesis have been performed at the Institute of Pharmacology, Erasmus University Rotterdam, the Department of Pharmacology. Duphar B.V., Weesp, The Netherlands and the Department of Pharmacology, Royal Free Hospital School of Medicine, London, U.K. The work was supported by Duphar B.V., Weesp. CONTENTS page CHAPTER I General introduction 1.1 Serotonin (5-HT) I l.l.l Localisation of 5-HT I 1.1.2 Function of 5-HT 2 1.2 5-HT receptors 2 1.2.1 Classification 2 1.2.2 Functional responses of 5-HT receptors 7 1.3 Overall regulation of the circulation II 1.3.1 Nervous control of the circulation 11 1.4 5-HT and cardiovascular regulation 13 1.4.1 5-HT and peripheral cardiovascular regulation 13 1.4.2 5-HT and central cardiovascular regulation 15 1.4.3 Cardiovascular effects of central 5-HT receptor interaction 18 1.5 The 5-HT1A receptor agonists 8-0H-DPAT and flesinoxan 20 1.6 Aim of the thesis 21 CHAPTER2 5-HT1A receptor agonist-induced cardiovascular effects 33 CHAPTER3 Systemic and regional haemodynamic effects of the 37 'putative 5-HT1A receptor agonist flesinoxan in the cat (Dreteler, G.H., Wouters, W. & Saxena. P.R. (1989) J. Cardiovasc. Pharmacol., 14, 770-776) CHAPTER4 Systemic and regional haemodynamic effects of the 5-HT1A 55 receptor agonists flesinoxan and 8-0H-DPAT in the conscious rat (Dreteler, G.H., Wouters, W., Toorop, G.P., Jansen, J.A.P. & Saxena. P.R. (in press) J. Cardiovasc. Pharmacol.) - i - CHAPTERS Comparison of the cardiovascular effects of the 5-HT1A 69 receptor agonist flesinoxan with that of 8-0H-DPAT in the rat (Dreteler, G.H., Wouters, W. & Saxena, P.R. (1990) Eur. J. Pharmacol., 180, 339-349) CHAPTER6 Cardiovascular effects of centrally administered 5-HT1A 89 receptor agonists CHAPTER7 Pressor effects following microinjection of 5-HT1A receptor 95 agonists into the raphe obscurus of the anaesthetized rat (Dreteler, G.H., Wouters, W., Saxena, P.R. & Ramage, A.G. (in press) Br. J. Pharmacol.) CHAPTERS Cardiovascular effects of microinjection of 5-HT, 109 8-0H-DPAT and flesinoxan into the hypothalamus of the rat (Dreteler, G.H., Wouters, W. & Saxena, P.R. (submitted) Eur. J. Pharmacol.) CHAPTER9 General discussion 123 9.1 The cardiovascular effects of 5-HT1A receptor agonists 123 9.2 The central mechanism of 5-HT1A receptor agonist­ 125 induced cardiovascular changes 9.3 Clinical significance of 5-HT1A receptor activation in 130 antihypertensive treatment SUMMARY 135 SAMENV AITING 139 LIST OF PUBLICATIONS 143 DANKWOORD 145 CURRICULUM VITAE 147 APPENDIX 149 - ii - CHAPTER 1 GENERAL INTRODUCTION 1.1 Serotonin The indole alkylamine serotonin (5-hydroxytryptamine; 5-HT) was isolated and chemically characterized about four decades ago, and is now generally accepted to function as a neurotransmitter and neuromodulatory agent. 5-HT is formed enzymatically from the essential amino acid tryptophan by hydroxylation, followed by decarboxylation (Fig. 1). Tryptophan tryptophan hydroxylase 5-Hydroxytryptophan aromatic L-amino acid decarboxylase 5-Hydroxytryptamine Fig. 1: Synthesis of 5-hydroxytryptamine. 1.1.1 Localisation of 5-HT 5-HT appears to be present in most plants and animals. In mammals. 5-HT is widely distributed and can be localized in nerve cells and fibers in specific brain areas (Dahlstrom & Fuxe, 1965; Steinbusch, 198 I ) as well as in several peripheral structures - 1 - like the enterochromaffin cells of the gastrointestinal mucosa, the pineal gland. blood platelets, nerves of the gastrointestinal tract and blood vessels, the blood vessel wall. in mast cells (rodents), and in lung, kidney, spleen, thyroid and heart tissue. With the exception of the platelets, 5-HT is synthesized in most tissues in which it is stored. Over 90% of the 5-HT content in the peripheral structures of the body is found in the enterochromaffin cells. From these cells 5-HT enters the circulation where it will be taken up by the platelets or removed by the liver or the endothelial cells in the lungs to be metabolized into 5-hydroxyindolacetic acid (5-HIAA) and excreted. 1.1.2 Function of 5-HT 5-HT exerts a variety of effects in the body. As the substance is not able to cross the blood brain barrier (Lexchin et al., 1977), there is an apparent discrimination between its peripheral and its central function. In the periphery 5-HT is involved in contraction of smooth muscle cells, aggregation of blood platelets and presynaptic depression of transmission in autonomic neurones. In the central nervous system 5-HT serves as a neurotransmitter and appears to play a role in the regulation of e.g. memory. appetite. anxiety, sleep, depression, body temperature, sexual behaviour and the cardiovascular system. 1.2 5-HT receptors 1.2.1 Classification Receptor site analysis has been one of the most productive approaches to understand the different actions of 5-HT in the central and peripheral nervous systems. In 1957. Gaddum and Picarelli described two distinct 5-HT receptor subtypes i.e. the 'D' and 'M' receptor. In guinea pig ileum, 5-HT evokes a contractile response resulting from activation of two different mechanisms: a direct action on the smooth muscle and an indirect action mediated by the release of acetylcholine from parasympathetic nerve endings. Because the former of these mechanisms was blocked by dibenzylline (D) and the latter by morphine (M), the excitatory 5-HT receptors on smooth muscle and parasympathetic nerve endings were designated D- and M-receptors. respectively. Although in this study the antagonists used were not selective for 5-HT, the distinction made between these two types of 5-HT receptors is still valid. - 2 - Following the development and application of radioligand binding techniques the existence of more different 5-HT receptor types became apparent. In 1974, Bennett and Aghajanian first successfully applied these techniques to serotonin receptors using [3H]LSD to label brain membrane sites. The second radioligand used to label 5-HT receptors was [3H]5-HT (Bennett and Snyder, 1976; Fillion et al., 1978; Nelson et al.. 1978). Further progress was made when [3H]spiperone also appeared to label 5-HT recognition sites. About two decades after the characterization of the 'D' and 'M' receptors by Gaddum and Picarelli, Peroutka and Snyder (1979) reported differences between the binding characteristics of [3H]5-HT, PH]LSD and PHJspiperone. Evidence was presented that [3H]5-HT and [3H]spiperone labelled distinct populations of 5-HT membrane recognition sites and that [3H]LSD appeared to label both these sites. In this paper the authors suggested to designate the binding sites labelled by [3H]5-HT as 5-HT1 and the binding sites labelled by [3H]spiperone as 5-HT2 receptors. The present state in the 5-HT receptor field is that there exist four main receptor populations, designated the 5-HT1 , 5-HT2 , 5-HT3 and the recently discovered 5-HT4 receptor. Initially, the distinction made between the 5-HT1 and the 5-HT2 receptor was purely based on radioligand binding studies using rather unselective drugs. Not until selective agonists and antagonists became available. could these 5-HT receptor sites be better characterized. In contrast with the 5-HT1 and 5-HT2 receptor types. the revelation of the 5-HT3 and 5-HT4 receptor types was at first based on functional receptor correlates. The development and discovery of selective drugs and, in the case of the 5- HT3 receptor, radioligand binding studies have provided more information on these 5-HT receptor populations. It became evident that the 5-HT1 subdivision of the 5-HT receptor family was heterogeneous. Pedigo and co-workers ( 1981) discovered a high and low affinity site for spiperone, designated as 5-HT1A and 5-HT16 recognition sites, respectively. A third subtype, based on the high affinity displacement of [3H]5-HT by the ergot derivative mesulergine, was identified in the choroid plexus of various animal species and designated as 5-HT1c binding site (Pazos et al .. 1985; Hoyer et al.. 1985). Most recently, based on studies of the bovine caudate nucleus using [3H]5-HT as radio ligand in the presence of 8-0H-DPAT (5-HT1A) and mesulergine (5-HTJC), the existence of a 5- HT10 recognition site has been reported (Heuring and Peroutka. 1987). Unfortunately. full characterization of the 5-HT1 binding sites was hampered, since few selective and specific agonists and no specific antagonists were available. So Bradley and co-workers - 3 - ( 1986) suggested to designate this heterogeneous receptor group as '5-HT1 -like ·, representing a group of binding sites for which 5-carboxamidotryptamine (5-CT) and 5- HT show a high affmity and the effects of 5-HT cannot be blocked by 5-HT2 or 5-HT3 receptor antagonists.
Recommended publications
  • Guaiana, G., Barbui, C., Caldwell, DM, Davies, SJC, Furukawa, TA
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Guaiana, G., Barbui, C., Caldwell, D. M., Davies, S. J. C., Furukawa, T. A., Imai, H., ... Cipriani, A. (2017). Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 2017(7), [CD012729]. https://doi.org/10.1002/14651858.CD012729 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD012729 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Library at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012729/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Cochrane Database of Systematic Reviews Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis (Protocol) Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A. Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2017, Issue 7.
    [Show full text]
  • Smoking Modulates Neuroendocrine Responses to Ipsapirone in Patients with Panic Disorder A
    Smoking Modulates Neuroendocrine Responses to Ipsapirone in Patients with Panic Disorder A. Broocks, M.D., Ph.D., B. Bandelow, M.D., Ph.D., K. Koch, U. Bartmann, J. Kinkelbur, M.D., U. Schweiger, M.D., Ph.D., F. Hohagen, M.D., Ph.D., and G. Hajak, M.D., Ph.D. Reduced 5-HT1A-receptor responsiveness has been reported temperature. In comparison to placebo, administration of in patients with panic disorder(PD) and/or agoraphobia ipsapirone was associated with significant increases of (PDA). Although many of these patients are regular various psychological symptoms and plasma cortisol smokers, it has not been examined whether psychological or concentrations. The subgroup of PD patients who were neurobiological effects induced by the selective 5-HT1A- smokers showed significantly higher cortisol responses to receptor agonist, ipsapirone, are affected by the smoking ipsapirone than non-smokers. status of the patients. In conclusion, smoking status has to be taken into In order to clarify this question neuroendocrine account when assessing the responsiveness of 5-HT1A challenges with oral doses of ipsapirone (0.3 mg/kg) and receptors in patients with psychiatric disorders. The placebo were performed in 39 patients with PDA, and prevention of smoking during challenge sessions might not results were compared between patients who smoked (Ͼ10 be the ideal approach in heavy smokers, since sudden cigarettes per day, n ϭ 17) and patients who had been non- abstinence from smoking is likely to affect neurobiological smokers for at least two years (n ϭ 22). and possibly psychological responses to ipsapirone. Patients who were smokers (but did not smoke during [Neuropsychopharmacology 27:270–278, 2002] the challenge procedure) had significantly reduced baseline © 2002 American College of Neuropsychopharmacology.
    [Show full text]
  • Serotonergic Modulation of Suicidal Behaviour: Integrating Preclinical Data with Clinical Practice and Psychotherapy
    Serotonergic modulation of suicidal behaviour: integrating preclinical data with clinical practice and psychotherapy Vasileios Boulougouris, Ioannis Malogiannis, George Lockwood, Iannis Zervas & Giuseppe Di Giovanni Experimental Brain Research ISSN 0014-4819 Exp Brain Res DOI 10.1007/s00221-013-3669-z 1 23 Your article is protected by copyright and all rights are held exclusively by Springer- Verlag Berlin Heidelberg. This e-offprint is for personal use only and shall not be self- archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com”. 1 23 Author's personal copy Exp Brain Res DOI 10.1007/s00221-013-3669-z SeroTONIN Serotonergic modulation of suicidal behaviour: integrating preclinical data with clinical practice and psychotherapy Vasileios Boulougouris · Ioannis Malogiannis · George Lockwood · Iannis Zervas · Giuseppe Di Giovanni Received: 6 May 2013 / Accepted: 30 July 2013 © Springer-Verlag Berlin Heidelberg 2013 Abstract Many studies have provided important infor- with personality disorders), aiming to invite the reader to mation regarding the anatomy, development and func- integrate some aspects of the neurobiology of human sui- tional organization of the 5-HT system and the alterations cidal behaviour into a model of suicide that can be used in in this system that are present within the brain of the sui- a clinical encounter.
    [Show full text]
  • Mechanism of Action of Antidepressants and Mood Stabilizers
    79 MECHANISM OF ACTION OF ANTIDEPRESSANTS AND MOOD STABILIZERS ROBERT H. LENOX ALAN FRAZER Bipolar disorder (BPD), the province of mood stabilizers, the more recent understanding that antidepressants share has long been considered a recurrent disorder. For more this property in UPD have focused research on long-term than 50 years, lithium, the prototypal mood stabilizer, has events, such as alterations in gene expression and neuroplas- been known to be effective not only in acute mania but ticity, that may play a significant role in stabilizing the clini- also in the prophylaxis of recurrent episodes of mania and cal course of an illness. In our view, behavioral improvement depression. By contrast, the preponderance of past research and stabilization stem from the acute pharmacologic effects in depression has focused on the major depressive episode of antidepressants and mood stabilizers; thus, both the acute and its acute treatment. It is only relatively recently that and longer-term pharmacologic effects of both classes of investigators have begun to address the recurrent nature of drugs are emphasized in this chapter. unipolar disorder (UPD) and the prophylactic use of long- term antidepressant treatment. Thus, it is timely that we address in a single chapter the most promising research rele- vant to the pharmacodynamics of both mood stabilizers and MOOD STABILIZERS antidepressants. As we have outlined in Fig. 79.1, it is possible to charac- The term mood stabilizer within the clinical setting is com- terize both the course and treatment of bipolar and unipolar monly used to refer to a class of drugs that treat BPD.
    [Show full text]
  • 5-HT1A Receptor Agonist Affects Fear Conditioning Through Stimulations of the Postsynaptic 5-HT1A Receptors in the Title Hippocampus and Amygdala
    5-HT1A receptor agonist affects fear conditioning through stimulations of the postsynaptic 5-HT1A receptors in the Title hippocampus and amygdala Author(s) Li, XiaoBai; Inoue, Takeshi; Abekawa, Tomohiro; Weng, ShiMin; Nakagawa, Shin; Izumi, Takeshi; Koyama, Tsukasa European Journal of Pharmacology, 532(1-2), 74-80 Citation https://doi.org/10.1016/j.ejphar.2005.12.008 Issue Date 2006-02-17 Doc URL http://hdl.handle.net/2115/8408 Type article (author version) File Information EJP22907revisedFinal.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP 5-HT1A receptor agonist affects fear conditioning through stimulations of the postsynaptic 5-HT1A receptors in the hippocampus and amygdala. XiaoBai Lia, b, Takeshi Inouea, Tomohiro Abekawaa, ShiMin Weng b, Shin Nakagawaa, Takeshi Izumia, Tsukasa Koyamaa a Department of Psychiatry, Neural Function, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan bShanghai Mental Health Center, 600, Wan Ping Nan Lu, Shanghai 200030, China Correspondence to: Takeshi Inoue, MD, PhD, Department of Psychiatry, Neural Function, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo 060-8638, Japan. Tel: +81-11-706-5160; Fax: +81-11-706-5081; E-mail: [email protected] Abstract Evidence from preclinical and clinical studies has shown that 5-HT1A receptor agonists have anxiolytic actions. The anxiolytic actions of 5-HT1A receptor agonists have been tested by our previous studies using fear conditioning. However, little is known about the brain regions of anxiolytic actions of 5-HT1A receptor agonists in this paradigm. In the present study, we investigated the effects of bilateral microinjections of flesinoxan, a selective 5-HT1A receptor agonist, into the hippocampus, amygdala and medial prefrontal cortex on the expression of contextual conditioned freezing and the defecation induced by conditioned fear stress in rats.
    [Show full text]
  • Eptapirone | Medchemexpress
    Inhibitors Product Data Sheet Eptapirone • Agonists Cat. No.: HY-19946 CAS No.: 179756-58-2 Molecular Formula: C₁₆H₂₃N₇O₂ • Molecular Weight: 345.4 Screening Libraries Target: 5-HT Receptor Pathway: GPCR/G Protein; Neuronal Signaling Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : 50 mg/mL (144.76 mM; Need ultrasonic) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 2.8952 mL 14.4760 mL 28.9519 mL Stock Solutions 5 mM 0.5790 mL 2.8952 mL 5.7904 mL 10 mM 0.2895 mL 1.4476 mL 2.8952 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.24 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.24 mM); Clear solution 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.24 mM); Clear solution BIOLOGICAL ACTIVITY Description Eptapirone (F11440) is a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. IC₅₀ & Target 5-HT1A Receptor In Vitro The affinity of Eptapirone (F11440) for 5-HT1Abinding sites (pKi, 8.33) was higher than that of buspirone (pKi , 7.50), and somewhat lower than that of flesinoxan (pKi , 8.91).In vivo, Eptapirone (F11440) was 4- to 20-fold more potent than Page 1 of 2 www.MedChemExpress.com flesinoxan, and 30- to 60-fold more potent than buspirone, in exerting 5-HT1A agonist activity at pre- and postsynaptic receptors in rats (measured by, for example, its ability to decrease hippocampal extracellular serotonin (5-HT) levels and to increase plasma corticosterone levels, respectively).
    [Show full text]
  • Clinical Utility of Vilazodone for the Treatment of Adults with Major Depressive Disorder and Theoretical Implications for Future Clinical Use
    Neuropsychiatric Disease and Treatment Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use Mandeep Singh Background: Vilazodone is the latest approved antidepressant available in the United States. Thomas L Schwartz Its dual mechanism of action combines the inhibition of serotonin transporters while simultane- ously partially agonizing serotonin-1a (5-HT1A) receptors. This combined activity results in SUNY Upstate Medical University, Psychiatry Department, Syracuse, serotonin facilitation across the brain’s serotonergic pathways, which has been termed by the NY, USA authors as that of a serotonin partial agonist and reuptake inhibitor, or SPARI. Objective: The authors to review laboratory, animal model data, and human trial data to synthesize a working theory regarding the mechanism of antidepressant action of this agent and regarding its potential for additional indications. Methods: A MEDLINE and Internet search was conducted and the resultant evidence For personal use only. reviewed. Results: Vilazodone has randomized, controlled empirical data which has garnered it an approval for treating major depressive disorder. It combines two well-known pharmacodynamic mechanisms of serotonergic action into a novel agent. Although no head-to-head studies against other antidepressants are published, the efficacy data for vilazodone appears comparable to other known antidepressants, with associated gastrointestinal side effects similar to serotonin selective reuptake inhibitor and serotonin norepinephrine reuptake inhibitor antidepressants, but potentially with a lower incidence of sexual side effects and weight gain. Discussion: As a new option for the treatment of major depressive disorder, vilazodone, due to its unique SPARI mechanism of action, may hold promise for patients who cannot tolerate or have not responded to previous antidepressant monotherapies.
    [Show full text]
  • Increased Tonic Activation of Rat Forebrain 5-HT1A Receptors by Lithium Addition to Antidepressant Treatments
    Increased Tonic Activation of Rat Forebrain 5-HT1A Receptors by Lithium Addition to Antidepressant Treatments Nasser Haddjeri, Ph.D., Steven T. Szabo, B.Sc., Claude de Montigny, M.D., Ph.D., and Pierre Blier, M.D., Ph.D. The present study was undertaken to determine whether 21 days, a dose of 50 ␮g/kg of WAY 100635 was needed to lithium addition to long-term treatment with different increase significantly the firing activity of these neurons. classes of antidepressant drugs could induce a greater effect On the other hand, WAY 100635, at a dose of only 25 ␮g/ on the serotonin (5-HT) system than the drugs given alone. kg, increased significantly the firing rate of CA3 pyramidal Because 5-HT1A receptor activation hyperpolarizes and neurons in rats receiving both a long-term antidepressant inhibits the firing activity of CA3 pyramidal neurons in the treatment and a short-term lithium diet. It is concluded that dorsal hippocampus, the degree of disinhibition produced by the addition of lithium to antidepressant treatments the selective 5-HT1A receptor antagonist WAY 100635 was produced a greater disinhibition of dorsal hippocampus CA3 determined using in vivo extracellular recordings. In pyramidal neurons than any treatments given alone. The controls, as well as in rats receiving a lithium diet for 3 days, present results support the notion that the addition of the administration of WAY 100635 (25-100 ␮g/kg, IV) did not lithium to antidepressants may produce a therapeutic modify the firing activity of dorsal hippocampus CA3 pyramidal response in treatment-resistant depression by enhancing neurons.
    [Show full text]
  • A Brief Summary for 5-HT Receptors
    ndrom Sy es tic & e G n e e n G e f T o Watry and Lu, J Genet Syndr Gene Ther 2013, 4:2 Journal of Genetic Syndromes h l e a r n a r p DOI: 10.4172/2157-7412.1000129 u y o J & Gene Therapy ISSN: 2157-7412 Short Commentary Open Access A Brief Summary for 5-HT Receptors Watry S and Lu J* Department of Neuroscience and Department of Neurology, School of Medicine and Public Health, Waisman Center, University of Wisconsin, Madison, WI 53705, USA As a group of G protein-coupled receptors (GPCRs) and ligand- (Anpirtoline) [42]; CGS 12066B [43]; SB 216641 [44]; RU 24969 [45]; gated ion channels (LGICs), the serotonin (5-HT) receptors are CP 93129 [46]. found in the central and peripheral nervous systems. After activated Application value: Depression [47]; Anxiety [48]; Aggression by the neurotransmitter serotonin, their natural ligand, 5-HT [49]; Migraine [50]; Drug Addicton [51]; increased locomotor activity receptors mediate both excitatory and inhibitory neurotransmission [52]; brain reward mechanisms (agonist); Alcoholism [53]; Sleep [54]; by modulating the release of many neurotransmitters, including hypothermia [55]. glutamate, GABA, dopamine, epinephrine/norepinephrine, and acetylcholine, as well as many hormones, including oxytocin, prolactin, Receptor: 5-HT 1D [56] vasopressin, cortisol, corticotropin, and substance P, among others. 5-HT receptors influence various biological and neurological processes Structure: GPCR [56]. such as aggression, anxiety, appetite, cognition, learning, memory, Localization: Raphe nuclei; Cortex, Caudate, Globus Pallidus mood, nausea, sleep, and thermoregulation. Accordingly, 5-HT [57]; Basal Ganglia, Substantia Nigra, Hippocampal Formation, receptors are the target of a variety of pharmaceutical drugs, including Raphe Nuclei [58]; Caudate Nucleus, Lateral Geniculate Nuclei, Spinal many antidepressants, antipsychotics, anorectics, antiemetics, Trigominal Nucleus [32]; Globus Pallidus [59].
    [Show full text]
  • Serotonin (5HT), Fluoxetine, Imipramine and Dopamine Target Distinct 5HT Receptor Signaling to Modulate Caenorhabditis Elegans Egg-Laying Behavior
    Copyright © 2005 by the Genetics Society of America DOI: 10.1534/genetics.104.032540 Serotonin (5HT), Fluoxetine, Imipramine and Dopamine Target Distinct 5HT Receptor Signaling to Modulate Caenorhabditis elegans Egg-Laying Behavior Catherine M. Dempsey, Scott M. Mackenzie, Andrew Gargus, Gabriela Blanco and Ji Ying Sze1 Department of Anatomy and Neurobiology, College of Medicine, University of California, Irvine, California 92697-4040 Manuscript received June 18, 2004 Accepted for publication November 22, 2004 ABSTRACT Drugs that target the serotonergic system are the most commonly prescribed therapeutic agents and are used for treatment of a wide range of behavioral and neurological disorders. However, the mechanism of the drug action remain a conjecture. Here, we dissect the genetic targets of serotonin (5HT), the selective 5HT reuptake inhibitor (SSRI) fluoxetine (Prozac), the tricyclic antidepressant imipramine, and dopamine. Using the well-established serotonergic response in C. elegans egg-laying behavior as a paradigm, we show that action of fluoxetine and imipramine at the 5HT reuptake transporter (SERT) and at 5HT receptors are separable mechanisms. Even mutants completely lacking 5HT or SERT can partially respond to fluoxetine and imipramine. Furthermore, distinct mechanisms for each drug can be recognized to mediate these responses. Deletion of SER-1, a 5HT1 receptor, abolishes the response to 5HT but has only a minor effect on the response to imipramine and no effect on the response to fluoxetine. In contrast, deletion of SER-4, a 5HT2 receptor, confers significant resistance to imipramine while leaving the responses to 5HT or fluoxetine intact. Further, fluoxetine can stimulate egg laying via the Gq protein EGL-30, independent of SER-1, SER-4, or 5HT.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Centre for Reviews and Dissemination
    Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications Casacalenda N, Boulenger J P Authors' objectives To assess the efficacy of anxiolytics (alprazolam and azapirones) in major depressive disorder (MDD) and of antidepressants in generalized anxiety disorder (GAD), thereby exploiting the possible theoretical and clinical implications of this efficacy. Searching MEDLINE was searched from January 1980 to September 1997 for English language peer-reviewed articles using the following keywords: depressive disorders, anxiety disorders, generalized anxiety disorder, antidepressants, antianxiety agents, benzodiazepines and buspirone. Bibliographies of identified studies were examined. Study selection Study designs of evaluations included in the review Randomised, double-blind trials (RCT) with a sample size of 30 patients or more that compared anxiolytics and antidepressants in the acute treatment of GAD or MDD were included. Specific interventions included in the review The following therapies were studied: benzodiazepines including alprazolam, diazepam, and lorazepam; tricyclic antidepressants (TCA) including desipramine, amitryptilline, imipramine, and doxepin); azapirones (including buspirone, ipsapirone, and gepirone); and placebo. Duration of treatment ranged from 4 to 8 weeks. Participants included in the review Adult patients with generalised anxiety disorder (GAD) or major depressive disorder (MDD) who were not being simultaneously treated with psychotherapy
    [Show full text]